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initiating IFX treatment between 7/1/2007 and 7/31/2011. Index date was the date of 
first IFX claim; 6 months pre- and 12 months post-index were required. Medication 
Possession Ratio (MPR) was calculated as [total days on IFX therapy based on infu-
sion dates and assumed duration of action/360 days]; at least two infusions were 
required. MPR thresholds of ≥ 80% and ≥ 60% were used to classify adherent patients. 
All-cause and CD-related costs per patient per month by place of service were calcu-
lated, adjusted to 2011 dollars. Results: A total of 173 patients were identified, 156 
of which had at least 2 infusions. Mean age was 47.9 years, 59.5% were female, and 
53.8% had Commercial coverage. Across the MPR thresholds, adherent patients had 
significantly higher all-cause physician office visit costs, and lower other outpatient 
visit, emergency department and hospitalization costs than non-adherent patients. 
CD-related costs showed similar trends for physician office visit, other outpatient 
visit and hospitalization costs. IBD-drug related costs were significantly higher in 
the adherent group; all-cause pharmacy costs were similar between those adherent 
and non-adherent. Total CD-related costs were higher among adherent patients (80% 
MPR, $2532.5(±1439.8) vs. $1949.3(±1395.1), p-value 0.0002), while total all-cause costs 
were similar between groups (80% MPR, $3236.(±1717.0) vs. $3084.8(±1859.4), p-value 
0.2564). ConClusions: Although adherent patients have higher physician office 
visit and IBD-drug related costs, hospitalization cost was significantly higher for 
non-adherent patients resulting in similar total all-cause costs for both the adher-
ent and non-adherent groups. Further research should quantify the clinical value 
of greater adherence against this backdrop of cost neutrality.
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objeCtives: There is little research regarding the cost effectiveness of ostomy 
pouching systems. There is also limited evidence regarding the patient preferences 
of these devices. The aim was to investigate the patient preferences of individual 
characteristics of ostomy pouching systems. The aim was also to rank these char-
acteristics based on patient preferences. Methods: All ostomy pouching systems, 
within the Swedish reimbursement system, were documented and their individual 
characteristics (i.e. properties of the filter, base plate and pouch material etc) iden-
tified both for closed-end and open-end bags. The significance of the identified 
characteristics was validated by a group of stoma nurses and experts. A pilot test 
of the interview guide for the focus group interviews were also held, resulting in 
small changes of the guide. Stoma nurses at nine different clinics in in different 
areas of Sweden consecutively asked stoma patients to participate. Patients were 
included if they gave oral and written consent, had a colostomy or ileostomy for at 
least one year. The patients were requested, together with the other participants 
in the focus group, to rank these individual characteristics of the ostomy pouching 
systems. Results: In total, 53 patients were included in the nine focus groups 
performed (one from each of the nine participating clinics). The top ranked patient 
preferences regarding closed-end bags were that the filter should reduce smell and 
should not leak but also that the base plate has good adhesive properties as well 
as being skin friendly. The top ranked patient preferences regarding open-end bags 
were also that the filter should reduce smell and should not leak. The bag should 
be easy to empty but also that the base plate has good adhesive properties as well 
as being skin friendly. ConClusions: The top-ranked patient preferences were 
mainly characteristics regarding the filter and base plate.
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objeCtives: Canadian inflammatory bowel disease (IBD) patients treated with 
infliximab are predominantly managed through a nationwide case management 
system, named BioAdvance, providing access to care, educational tools, supplies and 
assistance programs. The aim of this study was to identify underlying factors that 
were associated with positive changes in health outcomes. Methods: Between 
August 1 and September 30, 2012, a web-based survey was provided to patients cur-
rently receiving infliximab therapy within BioAdvance. The cross-sectional survey 
included items on demographic, disease characteristics, services usage and prefer-
ence, and perception of health and work absenteeism. Patients were categorized 
according to health trajectories: declined in health (decliners), no improvement 
(non-changers), moderate improvement and large improvements (strong increas-
ers). Multivariable multinomial logistic regression was used to determine which 
factors were associated with different health trajectories. Results: 918 of 1160 
respondents were IBD patients reporting health status. Patients were treated for 
Crohn’s disease [CD] (66.1%), Ulcerative Colitis [UC] (26.6%) or 2 or more conditions 
(7.3%). Strong increasers were most prevalent (53.2%) and decliners least preva-
lent (3.7%). Strong increasers were more likely to use educational tools than non-
changers (adjusted odds ratio [aOR]: 1.65; 95% confidence interval [CI]: 1.03-2.64), to 
be treated for UC than CD (aOR: 2.05; 95%CI: 1.16-3.64) and to perceive BioAdvance 
as important (aOR: 2.52; 95%CI: 1.56-4.09). There were no factors distinguishing 
decliners from non-changers. Younger patients were less likely to miss workdays, as 
were French speaking patients and, consistent health trajectories, patients treated 
for UC (aOR: 0.68; 95%CI: 0.47-0.97). Patients were more likely to have missed work-
days prior to joining BioAdvance (aOR: 2.76; 95%CI: 2.02-3.76). ConClusions: IBD 
patients receiving infliximab within the nationwide case management system 
report a positive impact on health status and absenteeism. Our study identified 
factors about the program that aremore impactful (educational tools) and patient 
factors that could improve program outcomes.
impairment, and numerically greater decreases in absenteeism, versus placebo at 
all study weeks. Differences relative to placebo in change from baseline to Week 
26 were -0.3% for absenteeism (NS), -5.9% for presenteeism, -7.5% for overall work 
productivity loss, and -6.7% for daily activity impairment (all 3 P< 0.05). Assuming a 
40-hour work week, linaclotide reduced overall work productivity loss by 3.0 hours/
week at Week 26. This translates to 156 hours/year which, based on average US 
wages, corresponds to an avoided overall work loss of $93 per patient/week or $4,861 
per patient/year. ConClusions: Compared with placebo, once-daily linaclotide 
treatment significantly reduced overall work productivity loss and activity impair-
ment among IBS-C patients, with improvements seen at all measured time points 
over 26 weeks of treatment.
GastroIntestInal dIsorders – Patient-reported outcomes & Patient  
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objeCtives: To examine the association between adherence and site of care 
among individuals with inflammatory bowel disease (IBD) treated with inflixi-
mab. Methods: Adult patients with new claim(s) for infliximab (no claims for at 
least 360 days) between January 1, 2006 to December 31, 2009 and ≥ 2 IBD diagno-
ses of Crohn’s disease (CD; ICD-9-CM: 555.XX) or ulcerative colitis (UC; ICD-9-CM: 
556.XX) were identified from Thomas Reuters Marketscan® Databases. Patients were 
required to be continuously enrolled for 12 months before and after infliximab 
initiation (index date). Patients with evidence of another biologic or rheumatoid 
arthritis (ICD-9-CM: 714.XX) were excluded. Being adherent was defined as having 
an infliximab medication possession ratio (MPR) of ≥ 80%. MPR was calculated as 
the sum of unduplicated days of therapy based on infusion dates and duration of 
action from prescribing information, divided by 360 days. Site of care was obtained 
from the first infliximab infusion claim. Sites were divided into three settings: office, 
outpatient hospital and “other” (e.g., home, ER). Odds of being adherent versus 
non-adherent were compared for these settings in a logistic model controlling for 
patient characteristics and resource use variables. Results: 1646 IBD patients were 
identified; 57.4% CD and 42.6% UC. The mean (SD) age was 44.4 (15.6) years and 51.7% 
were male. On index, 1,052 (63.9%) patients had a site of care for office on their first 
infliximab infusion claim, 510 (31.0%) had outpatient hospital, and 84 (5.1%) had 
“other”. Patients in the office setting had greater odds of being adherent relative 
to outpatient hospital (p< 0.0001; OR 2.5, 95% CI [1.9, 3.2]) and ‘other’ (p= 0.0039; 
OR 2.1, 95% CI [1.3, 3.4]). Outpatient hospital was not significantly different than 
the ‘other’ location (p= 0.5204). ConClusions: Findings suggest that having an 
office site of care is associated with increased infliximab adherence relative to the 
outpatient hospital setting.
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objeCtives: To describe adherence in Crohn’s disease (CD) patients receiving 
infliximab (IFX) by site-of-care (SOC). Methods: The Humana claims database 
was utilized to identify patients aged 18-89 with CD newly initiating IFX treatment 
between 7/1/2007 and 7/31/2011. Index date was the date of first IFX claim; 6 months 
pre- and 12 month post-index were required. Medication Possession Ratio (MPR) 
was calculated as [sum days’ supply of IFX based on infusion dates and assumed 
duration of action]/[sum days’ between first infusion and last days supply of last 
infusion]; therefore patients required ≥ 2 infusions. SOC types included physician 
office, outpatient hospital department, and ambulatory infusion centers. SOC was 
classified as ≥ 75% of infusions from one site; patients without a majority of infu-
sions from one site were classified as mixed-site. Results: A total of 173 patients 
were identified; 156 had at least 2 infusions. Mean age was 47.9 years, 59.5% were 
female, and 53.8% had Commercial coverage. Hospital outpatient (48.0%) and physi-
cian office (36.4%) were the most common SOC for index dose; among those who 
reached the maintenance phase, this same trend was observed. Mean MPR was 
similar across SOC (range 0.8 to 0.9, p-value 0.4412). Further, the proportion of 
patients considered adherent (≥ 80% MPR) was 72.4% among patients with physi-
cian office as primary SOC. The proportion of patients with ≥ 80% MPR in the other 
site types were similar to that of physician office patients (61.3%, 71.4%, and 81.0% 
for hospital outpatient, ambulatory infusion centers, and mixed site, respectively; 
p-value= NS). ConClusions: IFX adherence rates among CD patients did not vary 
significantly across different sites of care. Research evaluating other factors, such 
as patients’ preferences and satisfaction, may be useful in further characterizing 
available sites of care and supporting optimal site of care selection.
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objeCtives: To describe health care costs among Crohn’s disease (CD) patients 
receiving infliximab (IFX) by different adherence thresholds. Methods: The 
Humana claims database was utilized to identify patients aged 18-89 with CD newly 
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with usual activities and 23.6% of patients with mobility. Visual Analogue Scale 
(VAS) QoL scores for quiescent and active UC patients were 78.41 (14.89) and 69.50 
(19.41) (p= 0.0205), respectively. Quiescent patients had insignificantly better scores 
in all SIBDQ elements (global, systemic, social, bowel, emotional), global scores for 
patients with quiescent and active UC were 5.08 (1.31) and 4.75 (1.26) respectively. 
WPAI:UC indicated high levels of unemployment (40.7%). On average: work time 
missed (12.25% (27.30)), impairment while working (20.46% (25.85)) and overall work 
impairment (26.47% (32.21)). Scores for impairment of non-work activity for quies-
cent and active patients were 17.10% (25.45) and 27.39% (28.62) (p= 0.0244), respec-
tively. ConClusions: Patients with active UC demonstrated lower QoL measured 
by VAS and greater impairment of non-work activities. UC patients experienced a 
high percentage of unemployment and significant productivity loss.
GastroIntestInal dIsorders – health care use & Policy studies
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objeCtives: Introduced in 2006 in England, the Better Care, Better Value (BCBV) indi-
cators aim to promote cost-effective prescribing in the NHS. Previous data presented 
at ISPOR showed that the total cost of statin prescriptions fell by 44% between 2007 
and 2012, and that much of this decrease was likely attributable to the prescription 
of generic atorvastatin following patent expiry of the proprietary form. This analysis 
aimed to evaluate patterns of proprietary prescribing of proton pump inhibitors (PPIs), 
another category of drugs identified by the BCBV indicators. Methods: Prescription 
Cost Analysis databases were reviewed (2007–2012). Data extracted were the number 
of prescription items dispensed yearly in the community in England for 5 commonly 
prescribed PPIs, the preparation class and net ingredient cost (NIC) of each item. 
The overall NIC (sometimes used as a proxy of budget impact to the NHS) for PPIs 
and the proportion of proprietary items prescribed each year for each drug were 
compared. Results: Between 2007 and 2012 the total NIC of PPIs decreased by 38%. 
Over the same period, the decrease in the proportion of proprietary prescriptions was 
greater for PPIs (78%) than previously reported for statins (65%); however, this did not 
translate into a greater saving in total NIC. This could be due to the higher average 
number of prescriptions per year and the higher average NIC per prescription item 
for statins than for PPIs. Analysing data for each PPI, we found dramatic decreases 
in proprietary prescribing (100% to < 11%) within two years following patent expiry 
of the proprietary form. ConClusions: There was a decrease in the proportion of 
proprietary prescribing of PPIs in England between 2007 and 2012, with rapid declines 
following patent expiry of proprietary drugs. This suggests that the BCBV indicator is 
being met for PPIs as well as for statins.
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objeCtives: IBD-specific quality measures calling for the use of steroid sparing regi-
mens (i.e., those involving anti-TNFs and non-biologic immunomodulators) were 
recently adopted by the Center for Medicare and Medicaid Services (CMS). However, 
many older patients have contraindications to anti-TNFs. Our objective was to 
describe drug utilization and patient characteristics among older IBD patients with 
anti-TNF contraindications. Methods: A retrospective cohort study was conducted 
using CMS’ national 5% sample for 2006-2009 including Medicare patients with ≥ 12 
months Parts A and B, ≥ 6 months Part D, an IBD diagnosis (≥ 2 claims for ICD-9CM 
555.xx or 556.xx) and contraindications to anti-TNFs (advanced CHF, malignancies). 
We described the prevalence and days of exposure to each IBD drug class. Patient 
characteristics associated with steroid exposure were examined using a negative 
binomial-logit hurdle model. Results: Among 10,362 patients, 18% (n= 1860; 53% 
CHF, 39% malignancy, 8% both CHF and malignancy) had contraindications to anti-
TNF therapy. The mean age was 79 years, 67% were female and 87% white. Steroid 
use ranged from 258-283 users per 1000 patients per year and averaged 123-145 mean 
annual treatment days for utilizers. Anti-TNFs and non-biologic immunomodula-
tors were used infrequently (anti-TNFs: 19-30 users per 1000 patients each year, 
non-biologic immunomodulators: 29-36 users per 1000 patients each year). Patients 
who were younger, white, receiving any IBD drug class except anti-TNFs, had poly-
pharmacy, more hospitalizations or absence of stroke history had greater odds of 
receiving steroids. Among steroid recipients, polypharmacy and anti-TNF use were 
associated with a 65% (23%-121%) and 79% (28%- 150%) greater number of steroid 
therapy days, respectively. ConClusions: Use of steroids exceeded steroid sparing 
regimens supporting the importance of the new quality measure as a strategy to 
improve care. Patients with anti-TNF contraindications are frequently appropriate to 
receive non-biologic immunomodulators and our findings suggest that these drugs 
are underutilized in this cohort.
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objeCtives: To assess the predictive value of patient-reported stool frequency and 
rectal bleeding for mucosal healing based on endoscopic evaluation in patients 
with active UC. Methods: Patients with active UC defined by a Mayo score of 6-12 
including an endoscopy subscore of ≥ 2 were randomized to receive placebo or goli-
mumab (GLM) 200mg/100mg or 400mg/200mg at weeks 0 and 2, respectively. Patient-
reported stool frequency and rectal bleeding from weeks 0 through week 6 were 
collected from the most recent consecutive 3-day period within the 2 weeks prior to 
the visit. Responder was defined as normalized stool frequency or no rectal bleeding. 
Mucosal healing is defined as an endoscopy subscore of the Mayo score of 0 or 1. 
Odds Ratio (OR), positive predictive value (PPV) and likelihood Ratio Positive (LR+) 
were estimated for predicting mucosal healing using normalized stool frequency 
or no rectal bleeding. Receiver Operating Characteristic (ROC) curve was developed 
based on different cut-off of combined stool frequency and rectal bleeding scores 
(0-6). Results: At week 0, 99% of patients reported abnormal stool frequency and 
86.9% reported rectal bleeding. Among patients who reported no rectal bleeding 
at week 6, 66.5% achieved mucosal healing compared to 16.0% of patients with 
rectal bleeding (OR= 9.9, p< 0.001, PPV= 0.65, LR= 3.0). Similarly, among patients with 
normalized stool frequency at week 6, 77.1% achieved mucosal healing vs. 32.8% % 
of patients with abnormal stool frequency at week 6 (OR= 6.9, p< 0.001, PPV= 0.77, 
LR= 5.3). On ROC curve, a cut-off of ≤ 2 on a combined stool frequency and rectal 
bleeding score resulted in a sensitivity of 85% and specificity of 70.6% for predicting 
mucosal healing at Week 6. ConClusions: Normalized stool frequency and no 
rectal bleeding are predictors for mucosal healing in patients with UC.
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objeCtives: To examine correspondences between PROs with changes in disease 
activity and treatment in patients with UC. PRO instruments assessed generic health-
related quality of life (HRQL; 12-item Short Form v2 [SF-12v2]), disease-specific HRQL 
(Shortened Inflammatory Bowel Disease Questionnaire [SIBDQ]), and work-related 
outcomes (WROs; Work Productivity and Activity Impairment Questionnaire: UC 
[WPAI:UC]). Methods: Adults with mild-to-moderate UC received MMX mesala-
mine 4.8 mg/d for 8 weeks in an open-label, prospective study (NCT01124149). PROs, 
and a modified UC-Disease Activity Index (UCDAI) that captured several symptoms, 
including stool frequency (SF) and rectal bleeding severity (RBS), were administered at 
baseline and Week 8. Spearman coefficients examined associations between changes 
in PROs and disease activity. Analysis of variance (ANOVA) models tested changes in 
scores over time, with Cohen’s d’s used to interpret effect sizes. ANOVAs examined 
PRO change scores as a function of improvement (≥ 1-point reduction) in SF and 
RBS. Results: 639 patients completed treatment. Change scores at Week 8 were 
large for SIBDQ (mean d = 0.93; range: 0.78, 1.16) and medium-to-large for SF-12v2 
(0.70; 0.52, 0.88) and WPAI:UC (–0.74; –0.34, –0.93). Changes in UCDAI total scores cor-
related most strongly with SIBDQ (average correlation = –0.41), followed by WPAI:UC 
(0.38) and SF-12v2 (–0.34). RBS improvement corresponded most strongly to SIBDQ 
(average d = 0.47) compared with SF-12v2 (0.41) and WPAI:UC (–0.38). SF improvement 
corresponded most strongly to WPAI:UC (average d = –0.67) versus SIBDQ (0.61) and 
SF-12v2 (0.58). ConClusions: Disease-specific HRQL showed greatest sensitivity to 
treatment and strongest response to improvements in RBS compared with generic 
HRQL or WROs. However, WROs showed the largest improvements in concordance 
with SF. PROs were more responsive to changes in SF than RBS. Results indicate that 
different PRO instruments, capturing different constructs, are sensitive to varying 
aspects of treatment-related improvements in UC disease activity.
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objeCtives: Ulcerative colitis (UC) is a chronic disabling condition associated with 
reduced quality of life (QoL). Little data exists on differences between patients with 
active versus quiescent UC regarding QoL and productivity loss. Methods: Patients 
with moderate/severe UC (Mayo score ≥ 6), ≥ 18 years who received conventional 
therapies during the previous year were recruited in Belgium, France, Germany, 
Greece, Italy, The Netherlands, Spain, Sweden, Switzerland, Turkey, and UK. Patients 
who received biologics, colectomy or ileo-anal J-pouch reconstruction were 
excluded. Patients were classified with quiescent or active UC; quiescence being 
clinical Mayo score ≤ 2, no sub-score> 1, no corticosteroids for two months or, if no 
endoscopy, partial Mayo score ≤ 2, no corticosteroids for two months. Patients com-
pleted EQ-5D-5L, Short Inflammatory Bowel Disease (SIBDQ) and Work Productivity 
Activity Impairment:UC (WPAI:UC) questionnaires. Quiescent and active patients 
were compared using chi-square and t-test. Results: 253 patients were included, 
mean (SD) age 46.6(16.2) years, 59% male, 250 patients completed questionnaires, 
218 (86%) had active UC. EQ-5D-5L indicated that 39.0% of patients had problems 
